Senti Bio Completes SENTI-202 Phase 1 AML Trial Enrollment
Early Phase 1 signals from Senti Biosciences’ off-the-shelf CAR-NK program in relapsed/refractory AML include MRD-negative, durable complete remissions with...
Upstream Bio Sees Positive Results in Phase 2 Asthma Trial
Upstream Bio’s Phase 2 VALIANT study in severe asthma cut annualized asthma exacerbation rate by 56% with verekitug 100...
Remarkable Results: Microbiotica’s MB310 Colitis Trial
Clinical remission was achieved in 63.2% (12/19) of patients treated with MB310 versus 30.0% (3/10) on placebo in an...
PathAI Expands AISight Platform for IBD Clinical Trials
PathAI has expanded its AISight Clinical Trials platform for inflammatory bowel disease with the launch of IBDExplore, joining its...
Septerna Presents Phase 1 Trial Data for Mast Cell Diseases
Septerna will present first-in-human, proof‑of‑mechanism data for SEP‑631, an oral MRGPRX2 negative allosteric modulator, at the AAAAI Annual Meeting...
FDA Approves Expanded Eligibility for Phase 3 PWS Trial
Aardvark Therapeutics secured U.S. IRB approval to amend its Phase 3 HERO protocol, lowering the minimum enrollment age from...
FDA Approves Teverelix Phase 2b Study for High-Risk Cancer
In prior testing, teverelix achieved rapid testosterone suppression with a 97.5% probability of castration shortly after dosing in a...
Clearmind Trial Reinforces Favorable CMND-100 Safety Profile
Clearmind reported no serious adverse events and continued good tolerability in six additional patients completing treatment in the second...
Argá Medtech PFA Shows 94% Durability in Burst-AF Trial
BURST-AF, a 101-patient first-in-human study of Argá Medtech’s Coherent Sine-Burst Electroporation platform, reported 100% procedural success and 94% overall...
First Youth Enrolled in Promising Pediatric T1D Afrezza Study
MannKind has enrolled the first patient in INHALE-1ST, a U.S. multi-center, single-arm study evaluating Afrezza (inhaled human insulin) initiated...